Neoantigen Cancer Vaccine Market: Current Analysis and Forecast (2022-2028)

Neoantigen Cancer Vaccine Market: Current Analysis and Forecast (2022-2028)

Neoantigens are tumor-specific antigens that are developed from mutated proteins only found in cancer cells. Neoantigen cancer vaccines are novel vaccines that utilize neoantigens to boost the immune system against tumor cells. Owing to this high specificity towards cancer cells, these vaccines have gained considerable momentum in the global market. Pharmaceutical companies is tremendously investing in research activities for the development of neoantigen cancer vaccines. For instance, in October 2020, Vaccibody signed an agreement with Genentech for the development and commercialization of DNA-based individualized neoantigen cancer vaccines.

The Neoantigen Cancer Vaccine Market is expected to grow at a steady rate of around 25% owing to a surge in the prevalence of cancer. According to GLOBOCAN, in 2020, there were about 19.3 million new cancer cases and approximately 10 million deaths. Thus, the surge in the incidences of cancer is expected to foster the adoption of neoantigen cancer vaccines. Moreover, the rising initiatives of the government and various non-profit organizations in spreading awareness regarding the prevention of cancer are expected to fuel the growth of the market. For instance, the World Health Organization’s Global Action Plan for Prevention and Control of Non-Communicable Diseases aims at decreasing premature death due to cancer, cardiovascular diseases, chronic respiratory diseases, and diabetes by around 25% by the year 2025.

• Based on product, the market is bifurcated into personalized neoantigen vaccine and off-the shelf neoantigen vaccine. The personalized neoantigen vaccine is expected to grow with a significant CAGR during the forecast period. Although no personalized vaccine has entered the global market, the pipeline is highly crowded suggesting an encouraging future of these therapeutics in the management of cancer. For instance, in 2022, Moderna, in collaboration with Merck, developed its novel mRNA personalized cancer vaccine (PCV), mRNA4157, a combination of validated defined neoantigens, predicted neoepitopes, and mutations in driver genes into a single mRNA concatemer (mRNA4650).
• On the basis of neoantigen type, the market is segmented into a nucleic acid, dendritic cell, tumor cell, and synthetic long peptide. The nucleic acid category is expected to hold a significant share of the market during the forecast period due to the rise in the number of product pipelines and their encouraging response in the clinical trials. For instance, in October 2021, BioNTech dosed first patient with individualized mRNA vaccine, autogene cevumeran in the adjuvant treatment of circulating tumor DNA (ctDNA) positive, surgically resected Stage II (high-risk)/Stage III colorectal cancer.
• On the basis of therapy type, the market is bifurcated into mono therapeutic regimens and combinational regimens. The combinational regimens is anticipated to grow with significant CAGR during the forecast period owing to their advantages in terms of efficacy and safety in comparison to mono therapeutic regimens. Moreover, the large number of ongoing clinical trials also suggests a promising future for this category. For instance, in October 2021, Innovent Biologics entered into a strategic collaboration with NeoCura to evaluate the combination of sintilimab from Innovent and individualized neoantigen vaccine NEO_PLIN2101 from NeoCura in multiple solid tumors.
• On the basis of application, the market is segmented into melanoma, breast cancer, gastrointestinal, lung cancer, and others. The lung cancer segment held the dominant share of the market in 2021 due to the growing number of patients with lung cancer. In addition, a robust pipeline of a neoantigen cancer vaccine for the treatment of lung cancer is also driving segmental growth. For instance, Tedopi developed by OSE Immunotherapeutics is the first neoantigen cancer vaccine to demonstrate clinically meaningful efficacy results associated with a better safety and quality of life profile in monotherapy in advanced or metastatic non-small cell lung cancer (NSCLC). The vaccine is currently present in late-stage clinical trial and is expected to gain approval in 2023.
• For a better understanding of the market adoption of the neoantigen cancer vaccine, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period mainly due to the surge in the prevalence of various cancers. According to the report titled "Cancer statistics in China and U.S., 2022: profiles, trends, and determinants" published in February 2022, compared to the 4,568,754 new cancer cases in China in 2020, the predicted number of new cancer cases for 2022 is 4,820,000. This increase in the new cases will directly increase the demand for cancer therapy, thus helping in the growth of the market during the study period. Moreover, domestic companies are also tremendously investing to gain a competitive edge in the market. For instance, in July 2020, Aichi Cancer Center collaborated with NEC Corporation to initiate a research study aiming to identify suitable neoantigens for vaccine use by using the neoantigen prediction system.
• Some of the major players operating in the market include F. Hoffmann-La Roche Ltd; AstraZeneca; Merck & Co., Inc.; Gritstone bio; ose-immuno; BioNTech SE; Agenus Inc.; Gilead Sciences, Inc.; BrightPath Biotherapeutics Co., Ltd; and Innovent.